Nordic Nanovector

339 articles about Nordic Nanovector

• Nordic Nanovector: Results For The Second Quarter And Half Year 2015

  8/26/2015

• Nordic NanovectorTo Present at Pareto Securities’ 6th Annual Health Care Seminar

  8/20/2015

• Nordic Nanovector: Second Quarter And Half Year 2015 Results Presentation And Webcast

  8/18/2015

• Nordic Nanovector: NANO – Mandatory Notification Of Trade

  6/19/2015

• Nordic Nanovector: Updated Results Of Ongoing Phase 1/2 Study With Betalutin In Relapsed CD37+ Non-Hodgkin Lymphoma Patients

  6/17/2015

• Nordic Nanovector Appoints New Scientific Advisory Board

  5/21/2015

• Nordic Nanovector Schedules First Quarter 2015 Results Presentation And Webcast

  5/13/2015

• Nordic Nanovector – Share Capital Increase Registered

  4/24/2015

• Nordic Nanovector: Results Of Phase 1 Study Of Betalutin In Patients With Non-Hodgkin Lymphoma To Be Presented At The International Conference On Malignant Lymphoma

  4/23/2015

• Nordic Nanovector: Nano – Mandatory Notification Of Trade

  3/25/2015

• Nordic Nanovector: Nano – Mandatory Notification Of Trade

  3/20/2015

• Nordic Nanovector - Recommendation Of The Nomination Committee

  3/3/2015

• Nordic Nanovector - Approved Listing Application

  2/25/2015

• Nordic Nanovector – Fourth Quarter Report 2014

  2/23/2015

• Nordic Nanovector – Fourth Quarter Report 2014

  2/23/2015

• Nordic Nanovector To Present At 7th Annual Biotech Showcase Conference In San Francisco On 13 January 2015

  1/9/2015

• Nordic Nanovector To Present At DNB Markets 5th Annual Health Care Conference Today

  12/11/2014

• Nordic Nanovector Patent Granted In Japan

  12/10/2014

• Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology

  12/8/2014

• Nordic Nanovector To Present Clinical Data From Phase I/II Trial On Betalutin™ At Upcoming American Society of Hematology Meeting

  12/3/2014